Enterprise Value

819.1M

Cash

342.6M

Avg Qtr Burn

-17.9M

Short % of Float

13.77%

Insider Ownership

12.54%

Institutional Own.

84.36%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Bitopertin (GlyT1 inhibitor) Details
erythropoietic porphyrias, X-linked protoporphyria

Phase 2

Update

DISC-0974 Details
Myelofibrosis, Anemia, Chronic kidney disease

Big Mover™

Susp. Mover™

Phase 1/2

Data readout

Bitopertin (GlyT1 inhibitor) Details
Anemia, Rare genetic disease

Phase 1/2

Update

DISC-3405 (formerly MWTX-003) Details
Polycythemia vera, Cancer, Blood cancer

Phase 1

Update

GEM103 Details
Age-related macular degeneration

Failed

Discontinued

GEM103 Details
Wet age-related macular degeneration , Age-related macular degeneration

Failed

Discontinued